Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.